COMMON STOCK PURCHASE WARRANT PREDICTIVE ONCOLOGY INC.Predictive Oncology Inc. • September 30th, 2019 • Orthopedic, prosthetic & surgical appliances & supplies • Kansas
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the funding of that certain senior secured promissory note dated September 27, 2019, in the original principal amount of $847,500.00 by the Company (as defined below) to the Lender (as defined below)) (the “Note”), Oasis Capital, LLC, a Puerto Rico limited liability company (the “Lender” and including any permitted and registered assigns, the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time during the Exercise Period, to purchase from Predictive Oncology, Inc., a Delaware corporation (the “Company”), up to 682,368 shares of Common Stock (as defined below) (the “Warrant Shares”) at the Exercise Price per share then in effect. The number of Warrant Shares for which this Warrant may be exercised is subject to adjustment in accordance with the terms hereof. This Warrant is issued by the Company as of
SECURITY AGREEMENTSecurity Agreement • September 30th, 2019 • Predictive Oncology Inc. • Orthopedic, prosthetic & surgical appliances & supplies • Kansas
THIS SECURITY AGREEMENT (this “Agreement”), dated as of September 27, 2019, is by and between PREDICTIVE ONCOLOGY INC., a Delaware corporation (the “Grantor”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (the “Secured Party”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 30th, 2019 • Predictive Oncology Inc. • Orthopedic, prosthetic & surgical appliances & supplies • Kansas
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 27, 2019, (the “Execution Date”), is entered into by and between PREDICTIVE ONCOLOGY INC., a Delaware corporation (the “Company”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (the “Buyer”).
AMENDMENT #1 TO THE AMENDED AND RESTATED SENIOR SECURED PROMISSORY NOTE ORIGINALLY ISSUED ON SEPTEMBER 28, 2018Predictive Oncology Inc. • September 30th, 2019 • Orthopedic, prosthetic & surgical appliances & supplies
THIS AMENDMENT #1 to the Note (as defined below) (the “Amendment”) is entered into on September 27, 2019 (the “Effective Date”), by and between Predictive Oncology, Inc. (f/k/a Precision Therapeutics, Inc.), a Delaware corporation (the “Company”), and L2 Capital, LLC, a Kansas limited liability company (the “Holder”, and together with the Company, the “Parties”).
